Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Eager, Robert M ^a,k   Casey, C Casey ^a   Senzer, Neil N ^a,b,c,d   Stephenson Jr , Joe ^e   Anthony, Stephen P ^f   O'Day, Steven J ^g   Frenette, Gary ^h   Pavlick, Anna C ⁱ   Jones, Barry ^j   Uprichard, Margaret ^j   Nemunaitis, John ^a,b,c,d  

^a Mary Crowley Cancer Research Centers   (United States)

^b TEXAS ONCOLOGY   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d GRADALIS INC   (United States)

^e Cancer Centers of the Carolinas   (United States)

^f Cancer Care Northwest   (United States)

^g Angeles Clinic and Research Institute   (United States)

^h CAROLINAS MEDICAL CENTER   (United States)

ⁱ NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^j Point Therapeutics   (United States)

^k UNIVERSITY OF HAWAII   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; TALABOSTAT; TEMOZOLOMIDE; THALIDOMIDE; VITESPEN; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; DIPEPTIDE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ARTICLE; BLOOD DISEASE; BLURRED VISION; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYANOSIS; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EAR DISEASE; EDEMA; ERYTHROCYTE COUNT; EYE DISEASE; FACE EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; GASTROINTESTINAL DISEASE; GENITAL EDEMA; HEART DISEASE; HEART INFARCTION; HEART PALPITATION; HUMAN; HYPOACUSIS; HYPOTENSION; INNER EAR DISEASE; KIDNEY FAILURE; LEUKOPENIA; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS POTENTIAL; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; ORBIT EDEMA; OVERALL SURVIVAL; PERFORMANCE; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PRURITUS; RIGOR; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TINNITUS; VOMITING; WEIGHT; DISEASE COURSE; DISEASE FREE SURVIVAL; MIDDLE AGED; PROGNOSIS; SKIN TUMOR; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CISPLATIN; DIPEPTIDES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 69549116763     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-263     Document Type: Article

References (33)

1. Legha SS Ring S Papadopoulos N Plager C Chawla S Benjamin R A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma Cancer 2029, 64:2024-1989. 10.1002/ 1097-0142(19891115)64:10<2024::AID-CNCR2820641010>3.0.CO;2-V
2. McClay EF Mastrangelo MJ Berd D Bellet RE Effective combination chemo/ hormonal therapy for malignant melanoma: Experience with three consecutive trials Int J Cancer 1992, 50:553-556. 10.1002/ijc.2910500410 1537621
3. Margolin KA Liu PY Flaherty LE Sosman JA Walker MJ Smith JW 3rd Fletcher WS Weiss GR Unger JM Sondak VK Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: A Southwest Oncology Group study J Clin Oncol 1998, 16:664-669. 9469356
4. Creagan ET Suman VJ Dalton RJ Pitot HC Long HJ Veeder MH Vukov AM Rowland KM Krook JE Michalak JC Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma J Clin Oncol 1999, 17:1884-1890. 10561229
5. Falkson CI Ibrahim J Kirkwood JM Coates AS Atkins MB Blum RH Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology Group study J Clin Oncol 1998, 16:1743-1751. 9586887
6. Keilholz U Goey SH Punt CJ Proebstle TM Salzmann R Scheibenbogen C Schadendorf D Liénard D Enk A Dummer R Hantich B Geueke AM Eggermont AM Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: A randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group J Clin Oncol 1997, 15:2579-2588. 9215828
7. Rosenberg SA Yang JC Schwartzentruber DJ Hwu P Marincola FM Topalian SL Seipp CA Einhorn JH White DE Steinberg SM Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b J Clin Oncol 1999, 17:968-975. 10071291
8. Ridolfi R Chiarion-Sileni V Guida M Romanini A Labianca R Freschi A Lo Re G Nortilli R Brugnara S Vitali P Nanni O Italian Melanoma Intergroup Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: Results from an Italian multicenter phase III randomized clinical trial J Clin Oncol 2002, 20:1600-1607. 10.1200/JCO.20.6.1600 11896110
9. Keilholz U Punt CJ Gore M Kruit W Patel P Lienard D Thomas J Proebstle TM Schmittel A Schadendorf D Velu T Negrier S Kleeberg U Lehman F Suciu S Eggermont AM Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: A randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group J Clin Oncol 2005, 23:6747-6755. 10.1200/ JCO.2005.03.202 16170182
10. Del Vecchio M Bajetta E Vitali M Gattinoni L Santinami M Daponte A Sertoli MR Queirolo P Bernengo MG Cascinelli N Multicentre phase III randomized trial of cisplatin, vindesine, and dacarbzine (CVD) versus CVD plus subcutaneous (sc) interleukin-2 (IL-2) and interferon-alpha 2b (IFN) in metastatic melanoma patients (abstract 2489) Proc Am Soc Clin Oncol 2003, 22:709a.
11. Atkins MB Lee S Flaherty LE Sosman JA Sondak VK Kirkwood JM A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated intergroup trial (abstr 2847) Proc Am Soc Clin Oncol 2003, 22.
12. Sasse AD Sasse EC Clark LG Ulloa L Clark OA Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma Cochrane Database Syst Rev 2007, 1. CD005413 17253556
13. Ives NJ Stowe RL Lorigan P Wheatley K Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: A meta-analysis of 18 trials involving 2,621 patients J Clin Oncol 2007, 25:5426-5434. 10.1200/JCO.2007.12.0253 18048825
14. Hill GJ 2nd Krementz ET Hill HZ Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7131, and 7131A) Cancer 7130, 53:1299-1305. 10.1002/ 1097-0142(19840315)53:6<1299::AID-CNCR2820530613>3.0.CO;2-4
15. Middleton MR Grob JJ Aaronson N Fierlbeck G Tilgen W Seiter S Gore M Aamdal S Cebon J Coates A Dreno B Henz M Schadendorf D Kapp A Weiss J Fraass U Statkevich P Muller M Thatcher N Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma J Clin Oncol 2000, 18:158-166. 10623706
16. Kirkwood JK Molecular Diagnosis, Prevention & Therapy of Melanoma New York: Marcel Dekker 1997, 219.
17. Avril MF Aamdal S Grob JJ Hauschild A Mohr P Bonerandi JJ Weichenthal M Neuber K Bieber T Gilde K Guillem Porta V Fra J Bonneterre J Saïag P Kamanabrou D Pehamberger H Sufliarsky J Gonzalez Larriba JL Scherrer A Menu Y Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: A phase III study J Clin Oncol 2004, 22:1118-1125. 10.1200/JCO.2004.04.165 15020614
18. Coutts SJ Kelly TA Snow RJ Kennedy CA Barton RW Adams J Krolikowski DA Freeman DM Campbell SJ Ksiazek JF Bachovchin WW Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptides J Med Chem 1996, 39:2087-2094. 10.1021/jm950732f 8642568
19. Adams S Jones B Characterization of innate effector cells involved in the anti-tumor activity of talabostat (PT-100) American Association of Cancer Research (AACR) 97th Annual Meeting. Washington, DC 2006.
20. Adams S Miller GT Jones B T-cell independent antitumor activity of talabostat (PT-100) as a single agent and in combination with chemotherapy in mice. Abstract #648 American Association of Cancer Research (AACR) 96th Annual Meeting Anaheim, CA Proc Amer Assoc Cancer Res 2005, 46:648.
21. Adams S Miller GT Jesson MI Watanabe T Jones B Wallner BP PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism Cancer Res 2004, 64:5471-5480. 10.1158/0008-5472.CAN-04-0447 15289357
22. Jones B Uprichard MJ PT-100 Investigator's Brochure 2004.
23. Jesson MI McLean PA Miller GT Adams S Aubin J Jones B Immune mechanism of action of talabostat: A dipeptidyl peptidase targeted antitumor agent (abstr. 1894) AACR Centennial Annual Meeting Proceedings, Los Angeles, CA 2007, 48.
24. Rosenblum JS Kozarich JW Prolyl peptidases: A serine protease subfamily with high potential for drug discovery Curr Opin Chem Biol 2003, 7:496-504. 10.1016/S1367-5931(03)00084-X 12941425
25. Garin-Chesa P Old LJ Rettig WJ Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers Proc Natl Acad Sci USA 1990, 87:7235-7239. 54718 2402505 10.1073/ pnas.87.18.7235
26. Scanlan MJ Raj BK Calvo B Garin-Chesa P Sanz-Moncasi MP Healey JH Old LJ Rettig WJ Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers Proc Natl Acad Sci USA 1994, 91:5657-5661. 44055 7911242 10.1073/pnas.91.12.5657
27. Park JE Lenter MC Zimmermann RN Garin-Chesa P Old LJ Rettig WJ Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts J Biol Chem 1999, 274:36505-36512. 10.1074/jbc.274.51.36505 10593948
28. Cunningham CC Talabostat Expert Opin Investig Drugs 2007, 16:1459-1465. 10.1517/13543784.16.9.1459 17714031
29. Nemunaitis J Vukelja SJ Richards D Cunningham C Senzer N Nugent J Duncan H Jones B Haltom E Uprichard MJ Phase I trial of PT-100 (PT-100), a cytokine-inducing small molecule, following chemotherapy for solid tumor malignancy Cancer Invest 2006, 24:553-561. 10.1080/07357900600894732 16982458
30. Uprichard MJ Jones B Phase 1 rising multiple-dose study of talabostat (PT-100) in healthy subjects. (Abstract #4215) American Society of Hematology (ASH), 46th Annual Meeting San Diego, CA: Blood 2004, 104(11):4215.
31. Al-Katib A Hurd DD Raju R Stephenson J Giles F Haltom E Uprichard MJ Phase 1 study of talabostat and rituximab in patients with indolent non-Hodgkin's lymphoma with primary resistance to or progression following rituximab. (Abstract #1403) American Society of Hematology (ASH), 46th Annual Meeting San Diego, CA: Blood 2004, 104(11):1403.
32. Narra K Mullins SR Lee HO Strzemkowski-Brun B Magalong K Christiansen VJ McKee PA Egleston B Cohen SJ Weiner LM Meropol NJ Cheng JD Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer Cancer Biol Ther 2007, 6:1691-1699. 18032930
33. Balch CM Buzaid AC Soong SJ Atkins MB Cascinelli N Coit DG Fleming ID Gershenwald JE Houghton A Jr Kirkwood JM McMasters KM Mihm MF Morton DL Reintgen DS Ross MI Sober A Thompson JA Thompson JF Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma J Clin Oncol 2001, 19:3635-3648. 11504745